Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hebrew University
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
- Academic and Research Institutions
- Other Names / Subsidiaries
- The Hebrew University of Jerusalem
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.